SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References
  8. Supporting Information

Tenofovir (TDF) is considered the ideal treatment for patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). However, certain coinfected patients exhibit incomplete viral suppression, with persistent, and sometimes transient, bouts of HBV replication. The reasons for this, including clinical effect, are unclear. A total of 111 HIV-HBV-infected patients undergoing TDF-containing antiretroviral therapy were prospectively followed. Serum HBV-DNA viral load, hepatitis surface (HBsAg) and e antigen (HBeAg) status were obtained at baseline and every 6-12 months. Amino acid (aa) changes on the polymerase gene were assessed using direct sequencing after nested polymerase chain reaction in patients with persistent viremia (PV). After a median of 74.7 months (interquartile range: 33.4-94.7), virological response (VR; <60 IU/mL) occurred in 96 of 111 (86.5%) patients. Of these, 86 of 96 (89.6%) remained completely undetectable during follow-up (stabilized VR). The remaining 10 of 96 (10.4%) patients had a transient blip of detectable HBV-DNA (transient PV), during which time 9 of 9 (100%) with available samples had detectable plasma TDF. Low-level PV (LL-PV; 61-2,000 IU/mL) was observed in 11 of 111 (9.9%) patients, the majority of which had detectable plasma TDF (8 of 9; 88.9%). High-level PV (>2,000 IU/mL) was rare (4 of 111; 3.6%) and was associated with nonadherence. At TDF initiation, patients with stabilized VR had significantly higher nadir CD4+ count, compared to those with transient PV (P = 0.006) or LL-PV (P = 0.04). No consistent aa changes, other than those associated with lamivudine resistance, were observed in patients with persistent viremia. Importantly, HBeAg loss, HBeAg seroconversion, and HBsAg loss only occurred in patients with stabilized VR. Two patients with stabilized VR developed hepatocellular carcinoma and 2 with LL PV died, 1 of a liver-related cause. Conclusion: Suboptimal HBV control during TDF treatment has a negative effect on serological outcomes, but not necessarily clinical events. Immunoregulation may provide more insight into this phenomenon. (Hepatology 2014;60:497–507)

Abbreviations
aa

amino acid

aOR

adjusted odds ratio

ADV

adefovir

ALT

alanine transaminase

ARV

antiretroviral

AST

aspartate transaminase

CI

confidence interval

ETV

entecavir

FTC

emtricitabine

HBeAg

hepatitis B e antigen

HBsAg

hepatitis B surface antigen

HBV

hepatitis B virus

HCC

hepatocellular carcinoma

HCV

hepatitis C virus

HDV

hepatitis D virus

HIV

human immunodeficiency virus

HL-PV

high-level persistent viremia

IQR

interquartile range

LAM

lamivudine

LL-PV

low-level persistent viremia

LOWESS

locally weighted scatterplot smoothing

NA

nucleoside/nucleotide analog

PCR

polymerase chain reaction

Peg-IFN

pegylated interferon

PEIU

Paul Ehrlich Institute units

pol

polymerase

PV

persistent viremia

qHBeAg

quantification of hepatitis B e antigen

qHBsAg

quantification of hepatitis B surface antigen

RT

reverse transcriptase

TDF

tenofovir

VL

viral load

VR

virological response

In patients infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV) has emerged as a major cause of morbidity and mortality, accounting for substantial rises in cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease.[1] The incidence of these diseases can be greatly curbed by controlling HBV replication.[2, 3] There are currently a variety of antiviral drugs available for suppressing HBV, such as lamivudine (LAM), adefovir (ADV), entecavir (ETV), and tenofovir (TDF). The lattermost antiviral is ideal for treating coinfected patients as a result of its dual anti-HBV and -HIV activity as well as superior potency in suppressing HBV-DNA replication.[4, 5] Coupled by the fact that no mutations associated with TDF resistance have been consistently described in both HBV- and HIV-HBV- infected patients over extensive follow-up,[4, 6] it would then appear that optimal HBV suppression could be easily achieved in coinfected patients.

However, recent data have emerged suggesting that some patients exhibit suboptimal virological suppression after long periods of antiretroviral (ARV) therapy, where serum HBV-DNA could transiently, and even persistently, replicate.[7] A number of reasons for persistent viremia have been broached in the literature. First, guidelines often point toward poor adherence as a major source of unfavorable virological outcomes,[8] which may likely be the case given previous research.[6, 7] Second, HBV-specific T-cell response and intrahepatic T-cell activation are diminished in the presence of HIV, with incomplete reconstitution during prolonged ARV therapy.[9, 10] Immunological features of HIV-HBV coinfection, including degree of immunosuppression, might explain why certain patients exhibit suboptimal HBV suppression. Third, data from in vitro studies suggest that certain amino acid (aa) substitutions on the polymerase (pol) gene, in combination with precore mutations, can give rise to TDF resistance,[11, 12] despite strong clinical evidence against it.[13, 14]

The aim of the present study was then to thoroughly evaluate various virological and clinical characteristics in explaining suboptimal virological suppression in HIV-HBV coinfected patients undergoing extensive treatment with TDF-containing ARV therapy. We then develop our analysis by further exploring the effect of persistent viremia on HBV serological outcomes, which include two markers gaining substantial interest in predicting therapeutic success—hepatitis B surface antigen quantification (qHBsAg) and hepatitis B e antigen quantification (qHBeAg).[15] Finally, we wished to determine whether patients experiencing persistent viremia are at risk of developing liver-related morbidity or mortality.

Patients and Methods

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References
  8. Supporting Information
Patients

Patients were selected from the French HIV-HBV Cohort Study.[16] Briefly, this prospective study recruited 308 patients from seven centers located in Paris and Lyon, France, during May 2002–May 2003. Patients were included if they had HIV-positive serology confirmed by western blotting and HBsAg-positive serology for at least 6 months. Data collection continued until 2010-2011.

We retained individuals from a previous analysis of 143 patients undergoing a TDF-containing ARV regimen.[15] Additionally, we decided to only include patients with ≥12 months of follow-up, because virological response in patients undergoing nucleoside/nucleotide analog (NA) therapy may require extensive periods of follow-up to be fully evaluated,[17] particularly in HIV-HBV coinfection. As a result, 13 patients were excluded. Second, follow-up was right censored for patients who discontinued TDF use or had pegylated interferon (Peg-IFN) intensification, resulting in the exclusion of, respectively, 7 and 5 patients because of short follow-up (<12 months). Finally, patients with baseline hepatitis C virus (HCV)- or hepatitis D virus (HDV)-positive serology had been excluded in the previous analysis. However, we additionally excluded patients with incident HCV infection (n = 2) or with HCV/HDV infection later discovered during follow-up (n = 5). Thus, 111 patients were included in the present analysis. All patients provided written informed consent to participate in the cohort and the protocol was approved by the Pitié-Salpêtrière Hospital Ethics Committee (Paris, France) in accord with the Declaration of Helsinki.

Quantification of Serum Viral Loads

HBV-DNA viral loads (VLs) were obtained at TDF treatment initiation and every 6-12 months during follow-up. Commercial polymerase chain reaction (PCR)-based assays were used to quantify HBV-DNA VL (COBAS AmpliPrep/COBAS TaqMan HBV Test; detection limit: 12 or 38 IU/mL; COBAS Amplicor HBV Monitor Test; detection limit: 60 IU/mL; Roche Diagnostic Systems, Meylan, France). Because of varying detection limits, we decided to define undetectable HBV-DNA at the highest threshold (<60 IU/mL). HIV-1 VLs were measured using either a branched-DNA (Quantiplex 3.0; detection limit: 50 copies/mL; Bayer Diagnostics, Cergy Pontoise, France) or real-time PCR technique (COBAS AmpliPrep/COBAS TaqMan HIV-1 Test; detection limit: 40 copies/mL; Roche Molecular Systems).

HBV Replication Profiles

HBV replication profiles were defined a priori based on HBV-VL at the end of follow-up, where patients were initially classified on whether or not they had detectable HBV-VL. Among those with undetectable HBV-VL, patients were divided into two subgroups based on previous research7: stabilized virological response (VR; achieving and/or constantly maintaining HBV-DNA <60 IU/mL) or transient persistent viremia (PV; achieving <60 IU/mL, intermittently >60 IU/mL thereafter). Among those with detectable HBV-VL, patients were divided into two subgroups based on HBV-VL levels established from previous guidelines18: low-level persistent viremia (LL-PV; 60-2,000 IU/mL) or high-level persistent viremia (HL-PV; >2,000 IU/mL).

Plasma TDF Concentrations

Plasma TDF was measured using ultra performance liquid chromatography combined with tandem mass spectrometry (lower limit of quantification: 5 ng/mL; Waters Corporation, Milford, MA),[19] with the intent of assessing treatment adherence. Plasma concentrations were only performed in patients with PV. For patients with LL-/HL-PV, TDF was quantified at the last study visit. For patients with transient PV, TDF was quantified at the visit during which the blip in HBV replication occurred. If there was a prolonged blip (i.e., more than one consecutive visit with detectable HBV-VL), TDF concentrations were determined at the visit with the highest HBV-VL. To determine whether TDF concentrations were sufficient, we also quantified TDF levels in randomly selected patients with undetectable HBV-DNA (n = 34) at various visits during follow-up and compared them to patients with PV.

Genotypic Analysis

At baseline, L-nucleoside-associated pol gene mutations at positions rt173, rt180, and rt204 and precore mutations at nucleotide 1896 were determined using DNA chip technology (bioMérieux, Marcy l'Etoile, France).[20] During follow-up, genotypic analysis was performed in patients with PV. Samples were obtained at baseline and at the same visits used to quantify plasma TDF. aa substitutions of pol were examined by direct sequencing after nested PCR amplification of the reverse transcriptase (RT) encoding region, between aa 42-309, using the ANRS consensus method adapted from a previous work.[21] Sequences were analyzed using a sequence editing program (Seqscape; Applied Biosciences, les Ulis, France) and were further submitted to the “Genotypic prediction of HBV drug resistance” tool (Geno2pheno[HBV] 2.0; available at: http://hbv.bioinf.mpi-inf.mpg.de).

Serostatus and Quantification of Serological Markers

Qualitative hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and antibodies were detected at baseline and every yearly visit using a commercial enzyme-linked immunoassay (Diasorin, Antony, France).

Antigen levels were quantified at baseline and every 6-12 months during treatment. qHBsAg was performed using the Architect HBsAg assay (Abbott Laboratories, Rungis, France).[22] qHBeAg was determined using the Architect assay (with Architect i2000 analyzer) during the first 3 years of follow-up and the Elecsys HBeAg assay thereafter (with Modular E170 analyzer; Roche Diagnostics). Using a previously designed protocol,[23] signals from each assay were converted to Paul Ehrlich Institute units (PEIU)/mL. qHBeAg results from the Architect assay were then again converted into Elecsys units by an HIV-HBV-specific linear regression function. In other words, all qHBeAg units were expressed in PEIU/mL as if quantified from the Elecsys assay. Full details on the calculation of conversion factors are provided in the Supporting Methods (see the Supporting Information).

Assessing Liver-Related Parameters

Alanine transaminase (ALT) and aspartate transaminase (AST) were evaluated at baseline and every 6 months using standard methods. Baseline liver fibrosis levels were estimated using the noninvasive score FibroMeter, as detailed elsewhere,[24] and converted into Metavir equivalents. Liver biopsies were available in 64 patients at some point during therapy (18 with two biopsies) and evaluated using Metavir classification.[16] Any liver-related and non-liver-related clinical event was confirmed with the treating physician.

Statistical Analysis

Risk-factor analysis for undetectable HBV-DNA over time was carried out using random-effects logistic regression, accounting for within-patient variance. Time-varying factors were assessed by including the product of TDF treatment duration and the covariable of interest, including its individual components, to the model. All risk factors with P ≤ 0.2 in univariable analysis were used to create a predictive, multivariable model. A forward step-wise selection process was then performed, removing any covariable with a P value greater than the above-described threshold upon adjustment.

In patients with detectable HBV-DNA at baseline, undetectable HBV-DNA rates at 12 and 24 months, including 12-month change in HBV-DNA, were evaluated. qHBsAg and qHBeAg during treatment were initially examined by locally weighted scatterplot smoothing (LOWESS) plot, whereas 12-month change, 12-month change >1.0 log10 in IU/mL (qHBsAg) or PEIU/mL (qHBeAg), and maximum change (defined as the nadir decrease from baseline) were also evaluated. Average HIV-RNA log10 copies/mL levels during follow-up (while using 50 copies/mL as a uniform detection threshold) and percentage of visits with undetectable HIV-RNA VLs overall were also summarized.

Comparisons between HBV replication profiles were performed for all clinical parameters at baseline and during follow-up using Kruskal-Wallis' test for continuous variables and Pearson's chi-square test or Fisher's exact test for categorical variables, unless otherwise stated. In the subset of patients with liver biopsies, liver fibrosis levels were compared between HBV replication groups using a mixed-effect linear regression adjusted for TDF duration, while accounting for within-patient correlation for those with two biopsies.

All statistical analyses were performed using Stata software (v12.1; StataCorp LP, College Station, TX), and significance was determined using a P value <0.05.

Results

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References
  8. Supporting Information
Baseline Description of the Study Population

At TDF initiation, 78 (70.3%) patients were HBeAg positive and 92 (82.9%) had detectable HBV-DNA with a median HBV-DNA VL at 5.19 log10 IU/mL (interquartile range [IQR]: 3.16-7.01). All patients had previously initiated ARV therapy (median duration: 6.6 years; IQR, 4.2-8.5), thus median CD4+ cell count was at 396/mm3 (IQR, 292-552) and 62 (55.5%) had undetectable HIV-RNA. Of the 101 patients (91.0%) with previous LAM exposure, median LAM duration was 50.3 months (IQR, 31.2-71.2) at TDF initiation. Patients initiated TDF in combination with LAM (n = 82; 73.9%), alone (n = 24; 21.6%), with emtricitabine (FTC; n = 3; 2.7%), or with LAM plus FTC (n = 2; 1.8%).

Determinants of Undetectable HBV-DNA

Median follow-up was 74.7 months (IQR, 33.4-94.7). Risk factors of undetectable HBV-DNA VL over time are given in Table 1. Increased baseline HBV-DNA levels, longer duration of HBeAg-positive serology over time, and higher ALT levels over time were factors with significantly lower odds of undetectable HBV-DNA VL, whereas longer TDF duration was significantly associated with higher odds. Of note, neither cumulative LAM duration nor FTC duration were associated with undetectable HBV-DNA VL in multivariable analysis (adjusted odds ratio [aOR]/year = 1.00, 95% confidence interval [CI]: 0.99-1.01; aOR/year = 0.98, 95% CI: 0.97-1.01, respectively).

Table 1. Determinants of Undetectable HBV-DNA
 UnivariableMultivariableb
OR (95% CI)P ValueaOR (95% CI)P Value
  1. a

    Time-dependent covariate.

  2. b

    Adjusted for age at baseline, CD4+ cell count during follow-up, undetectable HIV-RNA, baseline HBV-DNA, HBeAg-positive status during follow-up, time (duration with TDF), and ALT levels during follow-up. Information on how the model was constructed can be found in the Supporting Results.

  3. Abbreviations: AIDS, acquired immune deficiency syndrome; aOR, adjusted OR; ART, antiretroviral therapy.

Age at baseline, per year1.06 (1.01-1.11)0.031.05 (0.98-1.12)0.15
Gender, females vs. males4.22 (1.13-15.77)0.03  
High HBV-endemic zone2.70 (1.00-7.32)0.05  
AIDS-defining event0.83 (0.37-1.89)0.7  
Nadir CD4+ cell count inline image at baseline1.38 (0.73-2.63)0.3  
CD4+ cell count, inline image    
At baseline1.42 (0.74-2.73)0.3  
During follow-upa1.03 (1.00-1.07)0.081.03 (0.99-1.06)0.12
Undetectable HIV-RNA5.35 (3.15-9.07)<0.0011.81 (0.83-3.94)0.14
HIV-RNA, per log10 copies/mL0.32 (0.23-0.45)<0.001  
Duration of ART (per year) at baseline0.95 (0.85-1.06)0.4  
HBV infection duration (per year) at baseline1.03 (0.96-1.10)0.4  
Baseline HBV-DNA, per log10 IU/mL0.64 (0.54-0.75)<0.0010.65 (0.50-0.85)0.002
qHBsAg, per log10 IU/mLa0.96 (0.92-0.99)0.04  
HBeAg positive    
At baseline0.10 (0.04-0.22)<0.001  
During follow-upa0.71 (0.58-0.87)0.0010.74 (0.61-0.89)0.001
TDF duration, per month1.14 (1.11-1.17)<0.0011.45 (1.19-1.77)<0.001
Previous LAM treatment1.77 (0.50-6.26)0.4  
Baseline LAM resistance mutations, N = 870.88 (0.37-2.10)0.8  
Baseline precore mutations, N = 890.99 (0.39-2.50)0.9  
Cumulative LAM duration, per yeara0.99 (0.98-1.00)0.16  
Cumulative FTC-duration, per yeara0.98 (0.96-1.00)0.04  
Concomitant LAM/FTCa0.97 (0.92-1.03)0.3  
ALT, >35 IU/mL    
At baseline0.29 (0.13-0.67)0.004  
During follow-upa0.95 (0.92-0.99)0.020.96 (0.93-0.99)0.03
AST, >35 IU/mL    
At baseline0.53 (0.24-1.14)0.11  
During follow-upa0.97 (0.93-1.00)0.08  
Distribution and Description of HBV Replication Profiles

Undetectable HBV-VL at the end of follow-up occurred in 96 (86.5%) patients, with 86 (77.5%) remaining completely undetectable during treatment (stabilized VR; Fig. 1). Among them, HIV-RNA was undetectable for a median 90.0% of study visits (IQR, 75.0%-100.0%). In the other 10 patients, detectable HBV replication was observed after a median of 8.8 months (range, 4.5-29.5) after having achieved undetectable HBV-VL (transient PV), during which time median peak HBV-DNA VL was 1,155 IU/mL (range, 68-7,162). Only 2 of these patients had a concomitant peak in qHBsAg during blip in HBV replication (Supporting Fig. 1). At the same time, plasma HIV-RNA was undetectable in 6 (60%) patients, low in 3 (30%; HIV-RNA VL range: 116-1,953 copies/mL), and fairly high in the remaining patient (HIV-RNA VL: 139,189 copies/mL).

image

Figure 1. Flow chart of HBV replication profiles.

Download figure to PowerPoint

In patients with detectable HBV-VL at the end of follow-up, LL-PV was observed in 11 (9.9%) patients, of whom 3 had achieved HBV VL <60 at least once during follow-up. In this group, median HBV-DNA VL was 111 IU/mL (range, 78-860) at the last visit. Meanwhile, HIV-RNA VL was undetectable for 7 (63.6%) patients and high for the remaining 4 (36.4%; range HIV-RNA VL: 3,421-590,000 copies/mL). HL-PV was found in 4 (3.6%) patients, among whom HBV-DNA ranged from 3.33 to 5.00 log10 IU/mL at the last visit. Only 1 patient achieved an undetectable HBV-VL during the course of follow-up. At the last visit, HIV-RNA was undetectable for 2 patients, whereas the remaining 2 had low HIV-RNA VLs (1,070 and 1,100 copies/mL).

Baseline Characteristics and HBV Replication Profiles

Table 2 describes the baseline characteristics of patients between profile groups. Because of small numbers of patients, LL-PV and HL-PV groups were combined for analysis. Among those with detectable baseline HBV-DNA, median HBV-DNA was higher for those with stabilized VR and LL-/HL-PV profiles than transient PV (P = 0.09 and 0.01, respectively). Patients with stabilized VR, as compared to all PV profiles, were significantly more likely to be HBeAg negative (P = 0.001) and have higher CD4+ nadir count (P = 0.004). Finally, stabilized VR and transient PV profiles had significantly lower baseline ALT/AST levels, when compared to LL-/HL-PV (P < 0.04).

Table 2. Baseline Characteristics of HBV Replication Profiles
CharacteristicsStabilized VR (n = 86)Transient PV (n = 10)LL-/HL-PVc (n = 15)P Valued
  1. a

    Median (IQR).

  2. b

    Number (%).

  3. c

    These groups were combined for analysis, yet the following significant differences were observed when only including the LL-PV group: BMI, versus transient PV, P = 0.04; nadir CD4+ cell count, versus stabilized VR, P = 0.04.

  4. d

    Significance determined using Kruskal-Wallis' test for continuous variables and Pearson's chi-square test or Fisher's exact test for categorical variables. Significant differences (P < 0.05) between HBV replication profile groups were indicated as follows: 1, stabilized VR and transient PV; 2, stabilized VR and LL-/HL-PV; 3, transient PV and LL-/HL-PV.

  5. e

    Among patients with detectable HIV-RNA or HBV-DNA viral loads.

  6. f

    Among HBeAg-positive patients.

  7. g

    Estimated using the noninvasive biochemical FibroMeter score.

  8. Abbreviations: cART, combination antiretroviral therapy; NS, no significant differences between groups; NTP, no test performed.

Demographics    
Gender, male/female (% male)76/10 (88.4)8/2 (80.0)15/0 (100)NS
Age, yearsa41 (36-48)42 (35-45)38 (33-45)NS
BMI, kg/m2a22.6 (20.9-24.0)23.3 (22.3-26.2)22.2 (20.5-23.4)NS
Born in high HBV endemic zoneb18 (20.9)2 (20.0)1 (6.7)NS
HIV characteristics    
AIDS-defining eventb23 (26.7)5 (50.0)5 (33.3)NS
Detectable HIV-RNAb33 (38.8)6 (60.0)5 (33.3)2
HIV-RNAe, log10 copies/mLa3.37 (2.57-4.12)4.56 (3.66-4.84)4.06 (2.08-4.81)ns
CD4+ cell count, per mm3a400 (324-576)185 (86-532)460 (219-514)1
Nadir CD4+ cell count, per mm3a238 (136-321)54 (30-179)124 (8-309)1
Duration of prior cART therapy, yearsa6.3 (3.5-8.6)6.8 (4.2-7.8)6.9 (6.0-8.4)ns
Viral hepatitis characteristics    
Known HBV infection duration, yearsa7.5 (3.0-12.0)9.7 (3.7-11.0)6.5 (2.8-9.1)NS
Prior LAM exposureb78 (90.7)9 (90.0)14 (93.3)NS
Detectable HBV-DNAb70 (81.4)7 (70.0)15 (100)NS
HBV-DNAe, log10 IU/mLa5.07 (3.18-7.15)2.95 (2.82-5.44)6.58 (4.58-7.28)3
HBeAg positiveb54 (62.8)10 (100)14 (93.3)1,2
qHBeAgf, PEI U/mLa497 (126-790)367 (81-701)363 (171-714)NS
qHBsAg, log10 IU/mLa    
HBeAg+4.74 (4.33-5.06)4.66 (3.66-5.09)4.79 (4.20-5.26)NS
HBeAg3.44 (2.84-3.65)3.51NTP
ALT, IU/La45 (30-83)40 (22-62)71 (51-149)2,3
AST, IU/La41 (27-61)28 (24-52)70 (40-85)2,3
F3-F4 fibrosisg, N = 98b19 (24.1)03 (23.1)NS
LAM-resistant mutations, N = 78b46 (79.3)4 (66.7)13 (92.9)NS
Precore mutations, N = 80b11 (16.7)2 (25.0)5 (33.3)NS
On-Treatment Virological and Serological Characteristics per HBV Replication Profile

In patients with detectable baseline HBV-DNA, median time until undetectable HBV-VL was not different between patients with stabilized VR versus transient PV profiles (12.6 vs. 23.2 months, respectively; Fig. 2A). In HBeAg-positive patients, it would appear that qHBeAg decline was faster in patients with stabilized VR and LL-/HL-PV profiles (Fig. 2B). These profile groups also had slightly steeper 12-month ΔqHBeAg, compared to transient PV profiles, with more patients exhibiting >1.0 log10 12-month PEIU/mL decreases (Table 3); however, there were no significant differences. Overall, faster 12-month decline in qHBsAg (Fig. 2C; Table 3) was also observed among patients with stabilized VR and LL-/HL-PV profiles versus transient PV (P = 0.15 and P = 0.04, respectively). Importantly, HBeAg-loss, HBeAg seroconversion, and HBsAg loss only occurred in patients with stabilized VR.

image

Figure 2. Time to undetectable HBV-DNA, qHBeAg, and qHBsAg levels between HBV replication profiles. Cumulative probability of time to undetectable HBV-DNA is compared between patients with stabilized VR versus transient PV using a log-rank test (A). LOWESS plots are also given by HBV replication profile group for qHBeAg (PEIU/mL) in HBeAg-positive patients (B) and qHBsAg (log10 IU/mL) in all patients (C). For the two latter plots, follow-up was truncated to 48 months in the combined LL-/HL-PV group. The low number of patients after this time point resulted in substantial variability, thus highly skewing the plot.

Download figure to PowerPoint

Table 3. Clinical and Serological Characteristics of HBV Replication Profiles During Follow-up
CharacteristicsStabilized VR (n = 86)Transient PV (n = 10)LL/HL PVf (n = 15)P Valueg
  1. a

    Median (IQR).

  2. b

    Among patients with detectable HBV-DNA at baseline.

  3. c

    Number (%).

  4. d

    Among HBeAg-positive patients.

  5. e

    Determined at the end of follow-up. Three patients had lost HBeAg, but later reconverted back to HBeAg-positive serology. Likewise, 1 patient had lost HBsAg, but later reconverted to HBsAg-positive serology.

  6. f

    These groups were combined for analysis, yet the only significant difference when including the LL-PV group alone was in maximum ALT decline versus transient PV (P = 0.04).

  7. g

    Significance determined using Kruskal-Wallis' test for continuous variables and Pearson's chi-square test or Fisher's exact test for categorical variables. Significant differences (P < 0.05) between HBV replication profile groups were indicated as follows: 1, stabilized VR and transient PV; 2, stabilized VR and LL-/HL-PV; 3, transient PV and LL-/HL-PV.

  8. Abbreviation: NS, no significant differences between groups.

Total follow-up, monthsa79 (33-95)86 (45-96)35 (23-40)2,3
HBV-DNAb    
Partial VR29 (41.4)3 (42.9)14 (93.3)2,3
12-month change, log10 IU/mLa−3.16 (−4.92, −1.30)−1.24 (−2.94, −0.24)−2.18 (−4.28, −1.27)NS
VR at 12 monthsc44 (62.9)2 (28.6)1 (6.7)2
VR at 24 monthsc54 (80.6)4 (57.1)1 (8.3)2,3
HIV-RNA    
Average HIV VL at last visit, log10 copies/mLa1.80 (1.71-1.99)1.94 (1.74-2.38)1.89 (1.63-3.00)NS
% detectable HIV VLs during follow-upa90.0 (75.0-100.0)82.9 (70.0-88.9)66.7 (0-100.0)2
≥70% detectable HIV VLs during follow-upc68 (80.0)7 (70.0)7 (46.7)2
qHBeAgd    
12-month change, PEI U/mLa−260 (−669, −33)−63 (−229, 0)−216 (−487, −158)NS
12-month change >1.0 log10c15 (27.8)03 (21.4)NS
Maximum change, log10 PEI U/mLa−2.03 (−2.70, −1.25)−1.51 (−1.62, −0.82)−1.02 (−1.36, −0.50)2
qHBsAg    
12-month change, log10 IU/mLa−0.33 (−0.80, −0.06)−0.14 (−0.32, −0.06)−0.29 (−0.78, −0.23)3
12-month change >1.0 log10c18 (20.9)03 (20.0)NS
Maximum change, log10 IU/mLa−0.77 (−1.44, −0.32)−0.81 (−1.48, −0.54)−0.93 (−1.40, −0.24)NS
Serological responsee    
HBeAg losscd20 (37.0)001,2
HBeAg seroconversioncd5 (9.3)00NS
HBsAg lossc4 (4.7)00NS
ALT    
Maximum decrease from baseline, IU/mLa−19 (−53, −9)−13 (−42, 0)−32 (−113, −10)NS
Maximum increase from baseline, IU/mLa10 (0, 35)22 (0, 41)4 (0, 71)NS
Last follow-up visit, IU/mLa31 (24-43)33 (20-41)43 (27-64)NS
Genotypic Characteristics of Patients With Persistent Viremia

Table 4 gives a complete description of the genotypic findings among patients with transient PV. Four of the six patients with available baseline sequences had LAM resistance mutations (rtM204V, n = 3; rtV173V/L+rtL180M+rtM204V: n = 1). At the time point where transient HBV replication occurred, the majority of mutations were associated with LAM resistance, with other aa changes observed at positions rtL217R (n = 2) and rtR274W (n = 1).

Table 4. Genotypic Findings of Patients With Transient PV
IDOther anti-HBV Treatment During FUaTDF Duration at BlipHBV-DNA (log10 IU/mL)TDF (ng/mL)GenotypeGenotypic Findings (pol Gene)
BaselineBlipBaselineChanges at Blip
  1. a

    Bold represents treatment given before TDF initiation.

  2. b

    This patient had HBV replication >106 log10 IU/mL for the first 12 months of therapy, during which time plasma TDF was not detected. Plasma samples were not available at the visit where transient replication occurred.

  3. c

    Changes confirmed with a previous sample at 20.1 months of TDF therapy.

  4. d

    This patient had a prolonged blip with three consecutive HBV-DNA levels at 3.06-3.86 log10 IU/mL.

  5. Abbreviations: FU, follow-up; Ø, no other anti-HBV treatment; n/a, HBV strain not sequenced, thus data are unavailable; —, virological data were not obtained for this visit.

119LAM23.72.823.4126ArtM204VrtV173L, rtL180M
145LAM[RIGHTWARDS ARROW]FTC46.22.441.8362GrtM204Vn/a
210LAM[RIGHTWARDS ARROW]Ø35.2<1.783.6767An/artV173L, rtL180M, rtM204V, rtL217R
301LAM[RIGHTWARDS ARROW]FTC[RIGHTWARDS ARROW]Ø67.25.571.83bErtM204VNone
407LAM[RIGHTWARDS ARROW]FTC[RIGHTWARDS ARROW]ADV36.84.583.2062ArtV173V/L, rtL180M, rtM204VNone
503LAM[RIGHTWARDS ARROW]Ø[RIGHTWARDS ARROW]FTC28.82.932.0673n/an/an/a
534LAM[RIGHTWARDS ARROW]Ø59.02.951.95103DrtH126R, rtY135CrtL217Rc
536LAM[RIGHTWARDS ARROW]Ø16.8<1.782.8520ArtV173L, rtL180M, rtM204V
540LAM[RIGHTWARDS ARROW]FTC21.75.443.86d54A/ENonertV173L, rtL180M, rtM204V
1134LAM19.5<1.783.6358n/artR274W

Among those with LL-PV (Table 5A), 3 of 4 patients with available baseline sequences had the triple rtV173L+rtL180M+rtM204V LAM resistance mutation, whereas 1 patient also harbored an HBV strain with aa changes at position rtL217R. During TDF treatment, no changes from baseline sequences were observed in these patients. Among those with HL-PV (Table 5B), all had LAM resistance mutations at baseline with other aa changes at positions rtL80I (n = 1) and rtL217R (n = 1). No other aa changes were noted during follow-up, except in 1 patient with a change at position rtV173L.

Table 5. Genotypic Findings of Patients With LL-PV and HL-PV
IDOther Anti-HBV Treatment During FUaTDF DurationHBV-DNA (log10 IU/mL)TDF (ng/mL)GenotypeGenotypic Findings (pol Gene)
BaselineEnd of FUBaselineChanges During FU
  1. Two patients were excluded because they had no available sample for testing (n = 2).

  2. a

    Bold represents treatment given before TDF initiation.

  3. b

    Information obtained from previous samples during TDF therapy with higher HBV-DNA viral load.

  4. c

    Mutation was no longer apparent at the end of follow-up.

  5. Abbreviations: FU, follow-up; Ø, no other anti-HBV treatment; n/a, HBV strain not sequenced, thus data are unavailable; —, virological/pharmacological data were not obtained for this visit.

A. LL-PV
105LAM24.38.472.1680An/a
152LAM[RIGHTWARDS ARROW]FTC81.28.302.00<5An/a
204LAM[RIGHTWARDS ARROW]FTC56.46.881.92142An/a
410LAM[RIGHTWARDS ARROW]Ø[RIGHTWARDS ARROW]FTC37.04.581.9499ArtV173L, rtL180M, rtM204V, rtL217RNoneb
502LAM[RIGHTWARDS ARROW]Ø35.17.851.8993An/a
1110LAM[RIGHTWARDS ARROW]Ø39.66.262.0984Gn/a
1131LAM33.42.942.9385ANoneNoneb
1140LAM18.92.611.95205DrtV173L, rtL180M, rtM204VNoneb
1155LAM36.65.062.8157ArtV173L, rtL180M, rtM204VNoneb
         
B. HL-PV 
208LAM[RIGHTWARDS ARROW]LAM/FTC96.66.884.94ArtL180Mc, rtM204GNone
1006LAM38.95.603.8630ArtL180M, rtM204VrtV173L
1022LAM24.86.585.00<5ArtV173L/V, rtL180M, rtM204V, rtL217RNone
1143LAM15.23.683.33<5ErtL80I, rtV173L, rtL180M/V, rtM204VNone
TDF Levels During PV

Among patients with transient PV, all 9 with available plasma samples had detectable TDF concentrations (median, 62 ng/mL; IQR, 54-67). In patients with LL-PV, 8 of 9 patients with available samples had TDF detected (median, 89 ng/mL; IQR, 82-121). Finally, in patients with HL-PV, 2 of 3 with available samples had plasma TDF <5 ng/mL, whereas the remaining patient was considered as having low TDF levels (30 ng/mL), according to the interval between last drug intake and sampling. Patients exhibiting PV did not have significantly different TDF concentrations, when compared to randomly selected patients with undetectable HBV-DNA (median, 65 ng/mL; IQR, 42-100; P = 0.6).

Transaminases and Liver-Related Outcomes

Overall, almost all patients observed declines in ALT levels, with a median maximum decline at -19 (IQR, -53, -8). Median maximum ALT decline only tended to be stronger in LL-/HL-PV than the transient PV group (P = 0.08; Table 3), which was expected given the high baseline transaminase levels in the LL-/HL-PV group. Otherwise, no other significant differences were observed in median maximum increase in ALT levels during follow-up or ALT levels at the last follow-up visit (Table 3).

No significant difference in Metavir equivalents (from the FibroMeter) was observed at baseline, yet no patient in the transient VR group had F3-F4 fibrosis (Table 2). In the subgroup with liver biopsies, taken after a median of 5.3 months of TDF (IQR, 0-27.7), there were no significant differences in Metavir fibrosis or activity level between stabilized VR and other PV groups: transient PV, 0.1 (95% CI: −0.7, 0.8; P = 0.9) or −0.1 (95% CI: −0.6, 0.4; P = 0.8); LL-/HL-PV, 0.5 (95% CI: −0.2, 1.2; P = 0.14) or 0.4 (95% CI: −0.1, 0.9; P = 0.09), respectively.

At TDF initiation, 3 patients had already experienced a severe liver-related event (n = 1, hepatic failure and n = 2, portal hypertension). Of these, 2 had stabilized VR and 1 had LL-PV. During TDF treatment, 2 patients developed HCC (both with stabilized VR replication profiles) and 2 died (both with LL-PV replication profiles). One death was the result of severe pneumonia, whereas the other was the result of a liver-related complication after the patient discontinued TDF therapy, resulting in an increase of HBV-DNA to 7.56 log10 IU/mL. No liver-related morbidity or mortality was observed in patients with HL-PV.

Discussion

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References
  8. Supporting Information

In this large, prospective study among patients on continuous TDF therapy for a median of 7 years, without ETV or Peg-IFN intensification, we demonstrate that 77.5% had optimal HBV suppression. In general, these patients were more likely to be either at later phases of HBV infection or have had more successful anti-HBV therapy preceding TDF initiation (higher proportion of HBeAg negative and lower ALT levels).

Poor adherence is often considered the first cause of persistent viremia to suspect among patients undergoing NA therapy with a high genetic barrier to resistance.[8] Although 18 of the 21 patients with persistent viremia and available samples had detectable plasma TDF at comparable levels to those with undetectable HBV-DNA, it may not give the overall picture of adherence over longer periods of time. Some clues can be inferred from rates of detectable HIV-RNA, where adherence reaching as low as 75% for some ARV classes is associated with effective HIV control.[25] Assuming that overall rates of undetectable HIV-RNA greater than 70% represent optimal adherence (HIV-RNA replication being explained by other factors, such as HIV resistance to non-nucleoside RT inhibitors or protease inhibitors[26]), PV could then be the result of fairly poor adherence in an estimated 11 of 25 patients. Still, the optimal adherence level for HBV suppression has not been determined; nevertheless, preliminary data suggest it to be much higher than HIV, from anywhere above 95%-100%.[7, 27]

Another potential reason of PV could be the genetic variability of HBV. The aa change at position rtL217R, which has already been identified with poor VR to ADV,[28] was observed in 4 patients. To the best of our knowledge, this specific mutation has not yet been phenotypically analyzed vis-à-vis tenofovir. A conserved site change at position rtR274W was also observed in 1 patient. A substitution located at the same position (rtR274Q/R) had been identified in 1 patient from the GS-US-174-0103 Study as the result of TDF discontinuation.[29] Interestingly, a highly mixed group of quasi-species was also found in this patient, whereas phenotypic evaluation of rtR274Q revealed a TDF-sensitive strain. Our study group has also identified a TDF-treated patient, not included in the present study, who harbored the possible TDF-resistance mutation, rtA194T, yet exhibited controlled HBV suppression.[20] Taken together, we found no dominant virological characteristic on the pol gene, at both baseline and follow-up, that was consistently associated with persistent replication. Wider ranges of sequencing would be necessary in determining whether mutations on the preS/S and preC/C regions of the HBV genome are also associated with ongoing replication. Moreover, one cannot exclude that PV may favor the occurrence of compensatory mutations, especially considering that higher variability of HBV quasi-species has been previously observed with poor response.[30]

Interestingly, patients with transient PV had significantly lower CD4+ cell counts, compared to other replication groups, whereas nadir CD4+ cell count was significantly lower among patients with PV overall. Because adaptive cellular mechanisms are intrahepatically impaired in HIV-HBV coinfection,[10] it could be hypothesized that the loss of HBV-specific immunological control in the liver might have elicited bouts of transient or low-level replication. Any changes in genetic variability observed during follow-up would likely be mere reflections of the quasi-species originating from a persistent reservoir, such as within hepatocytes. Of course, more-exhaustive data would be needed to address this hypothesis. It should be noted that nadir CD4+ cell count was not associated with undetectable HBV-DNA in univariable analysis. Yet, this analysis does not differentiate detectable HBV-DNA during normal treatment response versus PV, underscoring the importance of defining HBV replication groups.

Much ambiguity surrounds the clinical effect of persistent HBV replication in HIV-HBV coinfected patients. Data from the REVEAL-HBV study observed that among patients with HBV replication consistently at <104 copies/mL, the incidence rate of HCC was very low, at 73.4 per 100,000 person-years.[2] This association could be considered no different in coinfection, given the lack of increased risk in HCC between HIV-HBV- and HBV-infected patients.[31, 32] Indeed, inasmuch as our data were limited by the low incidence of clinical events, we could observe no evidence indicating that PV per se was linked to increased liver-related morbidity and mortality. Nevertheless, there was a clear link between consistently undetectable HBV-DNA and HBeAg loss, HBeAg seroconversion, and HBsAg loss, all of which are ideal therapeutic endpoints and correspond to decreased viral activity and improved liver-related outcomes.[17] This is in line with a previous study of HBV-monoinfected, NA-treated patients, where HBsAg loss only occurred in patients who were able to achieve HBV-DNA <300 copies/mL.[33]

One important and disconcerting observation was the significantly shorter duration of follow-up among patients with LL-/HL-PV, when compared to other groups. When matching follow-up of patients with LL-/HL-PV to those with stabilized VR or transient PV in a sensitivity analysis (Supporting Methods), we observed that 12.5% of the latter patients were reclassified as having some form of LL/HL virological persistence. Defining persistent replication at time points with short follow-up appears to be prone to misclassification. These changes did not substantially modify the analysis, especially with respect to serological endpoints (Supporting Tables 1-3); however, the 9 patients newly classified as HL-PV had characteristics typical of coinfected patients at risk of delayed response,[34] including high HBV-DNA and rather high increases in transaminase levels. This puts into question previous studies where detectable VL at 6-12 months is used as the hallmark of nonresponse or delayed response,[7, 30, 34] even as the majority of these patients eventually achieve VR.[35]

Our study has several limitations that need to be addressed. First, the threshold for transient HBV-DNA replication was particularly low and HBV VLs were only evaluated every 6-12 months. Patients with stabilized VR profiles could have been misclassified. Second, qHBeAg was obtained by two different assays and rendered similar using a post-hoc approach. Some bias could have been generated for certain measures, especially the 12-month change in qHBeAg. Finally, we did not record HIV resistance mutations during follow-up, which may have helped explain certain instances during which HIV-RNA was detectable.

In conclusion, PV hinders important serological endpoints during TDF treatment in HIV-HBV coinfected patients, yet this does not necessarily translate to increased risk in liver-related morbidity or mortality. No specific mutations on the pol gene were associated with PV, yet other genetic aspects of HBV need to be more thoroughly evaluated. Whether this phenomenon is caused by inadequate adherence remains to be concretely evaluated; nevertheless, our data suggest that roughly half of patients with PV were possibly the result of poor adherence. Other host factors, particularly immunoregulation, merit further investigation.

Acknowledgment

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References
  8. Supporting Information

The authors are grateful to the patients and the clinical teams for their commitment to the French HIV-HBV Cohort Study. The authors acknowledge H. Rougier, L. Roguet, and M. Sébire for managing the logistics of the French HIV-HBV Cohort; G. Pannetier and F. Carrat for their help in the data management; and Prof. P. Cales for kindly providing FibroMeter scores at baseline. Finally, the authors thank Prof. J.-F. Flejou and E. Roux of the Tumorothèque HUEP at Saint-Antoine Hospital for storing samples.

References

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References
  8. Supporting Information
  • 1
    Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012;61(Suppl 1):i47-i58.
  • 2
    Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011;141:1240-1248, 1248.e1-2.
  • 3
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
  • 4
    De Vries-Sluijs TEMS, Reijnders JGP, Hansen BE, Zaaijer HL, Prins JM, Pas SD, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010;139:1934-1941.
  • 5
    Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DKH, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218-1229.
  • 6
    Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014;59:434-442.
  • 7
    Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 2013;56:e87-e94.
  • 8
    Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012;56(Suppl 1):S112-S122.
  • 9
    Crane M, Sirivichayakul S, Chang JJ, Avihingsanon A, Ubolyam S, Buranapraditkun S, et al. No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol 2010;84:2657-2665.
  • 10
    Iser DM, Avihingsanon A, Wisedopas N, Thompson AJ, Boyd A, Matthews GV, et al. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS 2011;25:197-205.
  • 11
    Qin B, Budeus B, Cao L, Wu C, Wang Y, Zhang X, et al. The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. Antiviral Res 2013;97:93-100.
  • 12
    Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009;49:1158-1165.
  • 13
    Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247-254.
  • 14
    Lavocat F, Dény P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, et al. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol 2013;59:684-695.
  • 15
    Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, et al. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 2012;26:939-949.
  • 16
    Lacombe K, Massari V, Girard PM, Serfaty L, Gozlan J, Pialoux G, et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 2006;20:419-427.
  • 17
    European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
  • 18
    Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
  • 19
    Delahunty T, Bushman L, Fletcher CV. Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2006;830:6-12.
  • 20
    Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Miailhes P, et al. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology 2013;58:912-922.
  • 21
    Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085-1089.
  • 22
    Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004;115:217-222.
  • 23
    Maylin S, Boyd A, Martinot-Peignoux M, Delaugerre C, Bagnard G, Lapalus M, et al. Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. J Clin Virol 2013;56:306-311.
  • 24
    Boyd A, Lasnier E, Molina JM, Lascoux-Combe C, Bonnard P, Miailhes P, et al. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther 2010;15:963-974.
  • 25
    Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005;40:158-163.
  • 26
    De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, et al. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis 2013;207:1216-1220.
  • 27
    Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok ASF. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat 2012;19:205-212.
  • 28
    Rodriguez-Frias F, Jardi R, Schaper M, Buti M, Ferrer-Costa C, Tabernero D, et al. Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. Antivir Ther 2008;13:991-999.
  • 29
    Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-773.
  • 30
    Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, et al. Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. Antivir Ther 2012;17:61-70.
  • 31
    Walter SR, Thein HH, Amin J, Gidding HF, Ward K, Law MG, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011;54:879-886.
  • 32
    Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 2012;55:507-513.
  • 33
    Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010;17:16-22.
  • 34
    Childs K, Joshi D, Byrne R, Bruce M, Carey I, Agarwal K, et al. Tenofovir based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia. AIDS 2013;27:1443-1448.
  • 35
    Zoutendijk R, Reijnders JGP, Brown A, Zoulim F, Mutimer D, Deterding K, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology 2011;54:443-451.

Supporting Information

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References
  8. Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's website.

FilenameFormatSizeDescription
hep27182-sup-0001-suppinfo01.pdf75KSupporting Information.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.